Data Set

DESCRIPTION
ASSETS
Non-Current Assets
Property, Plant and Equipment- Carrying Value
Intangible Assets
Investment in Shares
Current Assets
Inventories
Spares & Supplies
Accounts Receivable
Loans, Advances and Deposits
Short Term Investment
Cash and Cash Equivalents
TOTAL ASSETS
EQUITY AND LIABILITIES
Shareholders Equity
Issued Share Capital
Share Premium
Excess of Issue Price over Face Value of GDRs
Capital Reserve on Merger
Revaluation Surplus
Retained Earnings
Fair Value Gain on Investment
Non-Current Liabilities
Long Term Borrowings-Net off Current Maturity (Secured)
Liability for Gratuity & WPPF
Deferred Tax Liability
Current Liabilities and Provisions
Short Term Borrowings
Long Term Borrowings-Current Maturity
Creditors and Other Payables
Accrued Expenses
Dividend Payable
Income Tax Payable
TOTAL EQUITY AND LIABILITIES
YEAR
2012
2011
18,567,329,474
18,364,313,070
198,223,509
4,792,895
16,392,388,639
16,201,858,216
187,079,147
3,451,276
15,884,877,780
15,745,492,625
135,933,879
3,451,276
8,903,422,328
2,411,881,986
433,352,407
1,249,434,697
1,186,637,111
3,026,383,161
595,732,966
8,197,421,953
2,433,987,981
396,175,790
1,162,404,807
965,276,373
2,686,598,326
552,978,676
7,148,462,753
2,291,844,631
325,881,244
978,224,317
840,320,705
2,193,423,560
518,768,296
27,470,751,802
24,589,810,592
23,033,340,533
19,775,552,465
3,503,349,070
5,269,474,690
1,689,636,958
294,950,950
1,349,578,805
7,667,220,373
1,341,619
18,408,161,859
3,046,390,500
5,269,474,690
1,689,636,958
294,950,950
1,406,527,880
6,701,180,881
-
17,128,128,177
2,517,678,100
5,269,474,690
1,689,636,958
294,950,950
1,466,602,600
5,889,784,879
-
3,312,618,059
1,151,400,702
610,628,150
1,550,589,207
3,116,703,964
1,469,621,611
499,622,784
1,147,459,569
3,257,050,368
1,890,074,651
403,598,795
963,376,922
4,382,581,278
2,776,266,125
754,903,558
383,170,553
3,064,944,769
1,526,449,918
664,712,728
470,097,685
2,648,161,988
1,642,216,008
363,744,181
523,798,136
141,582,304
973,367
325,685,371
128,598,961
1,020,948
274,064,529
101,559,917
1,361,452
15,482,294
27,470,751,802
24,589,810,592
23,033,340,533
Beximco Pharmaceuticals L
For the year ended 31 December 20
Balance sheet
For the year of 2011,2012 & 2013
2013
DESCRIPTION
ASSETS
workings for common size Bank

Statement
Actual Bank
Statement(BDT)
Non-Current Assets
2013:18567329474*100/27470751802;
2012 : 16392388639*100/24589810592 ;
2011: 15884877780*100/23033340533
18567329474
Property, Plant and Equipment- Carrying

Value
2013:18364313070*100/27470751802;
2012 : 16201858216*100/24589810592 ;
2011: 15745492625*100/23033340533
18364313070
Intangible Assets
2013:198223509*100/27470751802; 2012:
187079147*100/24589810592 ; 2011:
135933879*100/23033340533
198223509
2013: 4792895*100/27470751802;
2012: 3451276*100/24589810592 ;
2011: 3451276*100/23033340533
4792895
Current Assets
2013: 8903422328*100/27470751802;
2012: 8197421953*100/24589810592 ;
2011: 7148462753*100/23033340533
8903422328
Inventories
2013: 2411881986*100/27470751802;
2012: 2433987981*100/24589810592 ;
2011: 2291844631*100/23033340533
2411881986
Spares & Supplies
2013: 433352407*100/27470751802;
2012: 396175790*100/24589810592 ;
2011: 325881244*100/23033340533
433352407
Accounts Receivable
2013: 1249434697*100/27470751802;
2012: 1162404807*100/24589810592 ;
2011: 978224317*100/23033340533
1249434697
2013: 1186637111*100/27470751802;
2012: 965276373*100/24589810592 ; 2011:
840320705*100/23033340533
1186637111
2013: 3026383161*100/27470751802;
2012: 2686598326*100/24589810592 ;
2011: 2193423560*100/23033340533
3026383161
2013: 595732966*100/27470751802;
2012: 552978676*100/24589810592 ;
2011: 518768296*100/23033340533
595732966
TOTAL ASSETS
2013: 27470751802*100/27470751802;
2012: 24589810592*100/24589810592 ;
2011: 23033340533*100/23033340533
27470751802
2013: 19775552465*100/27470751802;
2012: 18408161859*100/24589810592 ;
2011: 17128128177*100/23033340533
19775552465

Shareholders Equity
2013: 3503349070*100/27470751802;
2012: 3046390500*100/24589810592 ;
2011: 2517678100*100/23033340533
3503349070
Share Premium
2013: 5269474690*100/27470751802;
2012: 5269474690*100/24589810592 ;
2011: 5269474690*100/23033340533
5269474690
Excess of Issue Price over Face Value of

GDRs
2013: 1689636958*100/27470751802;
2012: 1689636958*100/24589810592 ;
2011: 1689636958*100/23033340533
1689636958
2013: 294950950*100/27470751802;
2012: 294950950*100/24589810592 ;
2011: 294950950*100/23033340533
294950950
Revaluation Surplus
2013:1349578805*100/27470751802; 2012:
1406527880*100/24589810592 ; 2011:
1466602600*100/23033340533
1349578805
Retained Earnings
2013: 7667220373*100/27470751802;
2012: 6701180881*100/24589810592 ;
2011: 5889784879*100/23033340533
7667220373
2013: 1341619*100/27470751802
1341619
2013: 3312618059*100/27470751802;
2012: 3116703964*100/24589810592 ;
2011: 3257050368*100/23033340533
3312618059
2013: 1151400702*100/27470751802;
2012: 1469621611*100/24589810592 ;
2011: 1890074651*100/23033340533
1151400702
2013: 610628150*100/27470751802; 2012:

499622784*100/24589810592 ; 2011:
403598795*100/23033340533
610628150
Long Term Borrowings-Net off Current
Maturity (Secured)
2013: 1550589207*100/27470751802;
2012: 1147459569*100/24589810592 ;
2011: 963376922*100/23033340533
1550589207
2013: 4382581278*100/27470751802;
2012: 3064944769*100/24589810592 ;
2011: 2648161988*100/23033340533
4382581278
2013: 2776266125*100/27470751802;
2012: 1526449918*100/24589810592 ;
2011: 1642216008*100/23033340533
2776266125
2013: 754903558*100/27470751802; 2012:

664712728*100/24589810592 ; 2011:
363744181*100/23033340533
754903558
2013: 383170553*100/27470751802; 2012:

470097685*100/24589810592 ; 2011:
523798136*100/23033340533
383170553
Accrued Expenses
2013: 141582304*100/27470751802; 2012:

101559917*100/24589810592 ; 2011:
101559917*100/23033340533
141582304
Dividend Payable
2013: 973367*100/27470751802; 2012:

1020948*100/24589810592 ; 2011:
1361452*100/23033340533
973367
Income Tax Payable
2013: 325685371*100/27470751802; 2012:

15482294*100/24589810592 ; 2011:
15482294*100/23033340533
325685371
2013: 27470751802*100/27470751802;
2012: 23033340533*100/24589810592 ;
2011: 23033340533*100/23033340533
27470751802
maceuticals Limited
December 2011,2012 & 2013
11,2012 & 2013

2013
2012
2011
Common size(%)
Actual Bank
Statement(BDT)
Common size(%)
Actual Bank
Statement(BDT)
Common size(%)
68
16,392,388,639
67
15,884,877,780
69
67
16,201,858,216
66
15,745,492,625
68
0.72
187,079,147.00
0.76
135,933,879.00
0.6
0.02
3,451,276.00
0.014
3,451,276.000
0.015
32
8,197,421,953
33.34
7,148,462,753.00
31.04
8.8
2,433,987,981.0
9.90
2,291,844,631.00
10
1.6
396,175,790.0
1.6
325,881,244.0
1.4
4.5
1,162,404,807.0
4.7
978,224,317.0
4.25
965,276,373
840,320,705
3.65
11.02
2,686,598,326.00
11
2,193,423,560
9.5
2.17
552,978,676.00
518,768,296
2.25
100
24,589,810,592
100
23,033,340,533
100
72
18,408,161,859
75
17,128,128,177
74.4
13
3,046,390,500
12.39
2,517,678,100.00
11
19
5,269,474,690
21.4
5,269,474,690.0
23
6.15
1,689,636,958.00
1,689,636,958
7.34
1.07
294,950,950.00
1.20
294,950,950.00
1.3
4.91
1,406,527,880.00
5.7
1,466,602,600.0
6.37
28
6,701,180,881
27.25
5,889,784,879.00
25.6
0.005
12.06
3,116,703,964.00
13
3,257,050,368
14
4.19
1,469,621,611.00
1,890,074,651
8.21
2.22
499,622,784.00
2.03
403,598,795.00
1.75
5.64
1,147,459,569.00
4.67
963,376,922.00
4.18
16
3,064,944,769
12.46
2,648,161,988.00
11
10.11
1,526,449,918.00
6.21
1,642,216,008.00
7.13
2.75
664,712,728.00
2.70
363,744,181.00
1.6
1.39
470,097,685.00
523,798,136
2.27
0.52
128,598,961.00
0.44
101,559,917.00
0.44
0.00
1,020,948.00
0.004
1,361,452.000
0.01
1.19
274,064,529.00
0.07
15,482,294.00
0.07
100
24,589,810,592
100
23,033,340,533
100
Beximco Pharmaceuticals Limited

Statement of Comprehensive Income
Net Sales Revenue

Cost of Goods Sold
Gross Profit
Operating Expenses :
Administrative Expenses
Selling, Marketing and Distribution Expenses
Profit from Operations
Other Income
Finance Cost
Profit Before Contribution to WPPF
Contribution to Workers Profi t Participation/Welfare Funds
Profi t Before Tax
Income Tax Expenses
Current Tax
Deferred Tax Expense
Profi t After Tax for the Year
Other Comprehensive Income
Fair Value Gain on Investment in Listed Shares
Total Comprehensive Income for the Year
2013
Amount in Taka
2012
2011
10,490,699,094
-5,651,898,878
4,838,800,216
9,289,115,284
-4,899,713,857
4,389,401,427
7,890,241,843
-4,103,709,021
3,786,532,822
-2,514,527,446
-375,565,912
-2,138,961,534
2,324,272,770
-2,181,521,867
-332,225,347
-1,849,296,520
2,207,879,560
-1,798,053,124
-275,201,846
-1,522,851,278
1,988,479,698
510,588,200
-636,587,090
2,198,273,880
442,847,713
-645,406,575
2,005,320,698
340,907,774
-567,645,757
1,761,741,715
-104,679,709
-95,491,462
-83,892,463
2,093,594,171
-688,831,391
-324,415,546
-364,415,845
1,404,762,780
1,341,619
1,909,829,236
-590,439,908
-445,712,907
-144,727,001
1,319,389,328
-
1,677,849,252
-479,323,910
-207,549,905
-271,774,005
1,198,525,342
-
1,406,104,399
1,319,389,328
1,198,525,342

For the year ended 31 December 2011,2012 &
2013
Calculation for common size
statement
Actual Income
statement(in BDT)
Net Sales Revenue
2013: 10490699094*100/10490699094;
2012: 9289115284*100/9289115284;
2011: 7890241843*100/7890241843
10,490,699,094
Cost of Goods Sold
2013: -5651898878*100/10490699094;
2012: -4899713857*100/9289115284;
2011: -4103709021*100/7890241843
-5,651,898,878
Gross Profit
2013: 4838800216*100/10490699094;
2012:4389401427*100/9289115284;
2011: 3786532822*100/7890241843
4,838,800,216
2013: -2514527446*100/10490699094;
2012:-2181521867*100/9289115284;
2011: -1798053124*100/7890241843
-2,514,527,446
2013: -375565912*100/10490699094;
2012:-332225347*100/9289115284;
2011: -275201846*100/7890241843
-375,565,912
Description
2013: -2138961534*100/10490699094;
2012:-1849296520*100/9289115284;
2011: -1522851278*100/7890241843
-2,138,961,534
2013:2324272770*100/10490699094;
2012:2207879560*100/9289115284;
2011: 1988479698*100/7890241843
2,324,272,770
Other Income
2013:510588200*100/10490699094;
2012:442847713*100/9289115284;
2011: 340907774*100/7890241843
510,588,200
Finance Cost
2013:-636587090*100/10490699094;
2012:-645406575*100/9289115284;
2011: -567645757*100/7890241843
-636,587,090
2013:2198273880*100/10490699094;
2012:2005320698*100/9289115284;
2011: 1761741715*100/7890241843
2,198,273,880
2013:-104679709*100/10490699094;
2012:-95491462*100/9289115284;
2011: -83892463*100/7890241843
-104,679,709
Profi t Before Tax
2013:2093594171*100/10490699094;
2012:1909829236*100/9289115284;
2011: 1677849252*100/7890241843
2,093,594,171
Income Tax Expenses
2013:-688831391*100/10490699094;
2012:-590439908*100/9289115284;
2011: -479323910*100/7890241843
-688,831,391
Current Tax
2013:-324415546*100/10490699094;
2012:-445712907*100/9289115284;
2011: -207549905*100/7890241843
-324,415,546
2013:-364415845*100/10490699094;
2012:-144727001*100/9289115284;
2011: -271774005*100/7890241843
-364,415,845
Contribution to Workers Profi t

Participation/Welfare Funds
2013:1404762780*100/10490699094;
2012:1319389328*100/9289115284;
2011: 1198525342*100/7890241843
1,404,762,780
2013:1341619*100/10490699094
1,341,619
2013:1406104399*100/10490699094;
2012:1319389328*100/9289115284;
2011: 1198525342*100/7890241843
1,406,104,399

euticals Limited
rehensive Income
ember 2011,2012 & 2013
2013
2012
2011
Common Size
income
statement(in
%)
Actual Income
statement(in
BDT)
Common Size
Actual Income
Common Size
income
statement(in income statement(in
statement(in
BDT)
%)
%)
100
9,289,115,284
100
7,890,241,843
100
-54
-4,899,713,857
-53
-4,103,709,021
-52
46
4,389,401,427
47
3,786,532,822
48
-24
-2,181,521,867
-23
-1,798,053,124
-23
-4
-332,225,347
-4
-275,201,846
-3
-20
-1,849,296,520
-20
-1,522,851,278
-19
22
2,207,879,560
24
1,988,479,698
25
442,847,713
340,907,774
-6
-645,406,575
-7
-567,645,757
-7
21
2,005,320,698
22
1,761,741,715
22
-1
-95,491,462
-1
-83,892,463
-1
20
1,909,829,236
21
1,677,849,252
21
-6.6
-590,439,908
-6
-479,323,910
-6
-3.1
-445,712,907
-5
-207,549,905
-3
-3.5
-144,727,001
-2
-271,774,005
-3
13.4
1,319,389,328
14
1,198,525,342
15
0.013
13
1,319,389,328
14
1,198,525,342
15
Profitablity
Profitablity
ROE = Net Income/ Average Common Shareholders Equity
With Preferred Stock: ROE = (Net Income Preferred Dividend)/ Average Common Shareholders Equity
ROA = Net Income/Average Total Asset
Gross Profit Margin = Gross Profit/Sales
Net Profit Margin = Net Profit/ Sales
Liquidity
Current ratio = Current Asset/ Current Liabilities
Acid test ratio/ quick asset ratio = (Current Asset Inventory)/ Current Liabilities
Efficiency
Asset Turnover Ratio = Sales/ Average Total Assets

Inventory Turnover= Cost of Goods Sold/ Average Inventories
Accounts Receivables Turnover = Credit Sales/Average Accounts Receivables
Accounts Payable Turnover = Cost of Goods Sold/ Average Accounts Payable
Days inventory/ Inventory Conversion Period = 365/ Inventory Turnover
Average Collection Period = 365 / Accounts Receivables Turnover
Average Payment Period = 365/ Accounts Payable Turnover
Cash Conversion Cycle= (365/Inventory Turnover)+(365/Accounts Receivable Turnover)
Or
Cash Conversion Cycle= (365/Inventory Turnover)+(365/Accounts Receivable Turnover)- ( 365/Accounts Payable Turnover
Gearing
Debt to equity: Total Debt/ Shareholders Equity
Debt ratio: Total Debt/ Total Asset
Equity ratio: Shareholders Equity/ Total Asset
Interest coverage ratio: EBIT/ Interest
Market Performance
EPS = (Net Income Dividend on Preferred Stock)/ Weighted Average Number of Share Outstanding
Dividend payout ratio = Dividend paid per share/ Earning Per Share
PER = Price Per Share/ Earning Per Share
Number of Share outstanding
Price per share
Dividend
Dividend per share
DESCRIPTION
ASSETS
Non-Current Assets
Intangible Assets
Current Assets
Inventories
Spares & Supplies
Accounts Receivable
TOTAL ASSETS
Shareholders Equity
Share Premium
Revaluation Surplus
Retained Earnings
Accrued Expenses
Dividend Payable
Income Tax Payable

Net Sales Revenue

Cost of Goods Sold
Gross Profit
Other Income
Finance Cost
Contribution to Workers Profi t Participation/Welfare Funds
Profi t Before Tax
Income Tax Expenses
Current Tax
11111
2013
2012
2011
0.07
0.07
0.07
0.05
0.46
0.13
0.05
0.47
0.14
0.05
0.48
0.15
2.03
1.48
2.67
1.88
2.70
1.83
0.38
2.34
8.40
14.75
155.8
43.47
24.75
155.76
0.38
2.01
7.99
10.42
181.32
45.67
35.02
226.99
0.34
1.79
8.07
7.83
203.85
45.25
46.59
249.10
0.39
0.28
0.72
0.34
0.25
0.75
0.34
0.26
0.74
4.01
0.00
11.76
4.33
0.00
12.91
4.76
0.00
19.65
350,334,907
304639050
251676810
on Shareholders Equity
Turnover)- ( 365/Accounts Payable Turnover)
47.2
55.9
525502
0.001499999
456959
0.0015000014
2013
93.6
528712
0.0021007577
YEAR
2012
2011
18,567,329,474
18,364,313,070
198,223,509
4,792,895
16,392,388,639
16,201,858,216
187,079,147
3,451,276
15,884,877,780
15,745,492,625
135,933,879
3,451,276
8,903,422,328
2,411,881,986
433,352,407
1,249,434,697
1,186,637,111
3,026,383,161
595,732,966
8,197,421,953
2,433,987,981
396,175,790
1,162,404,807
965,276,373
2,686,598,326
552,978,676
7,148,462,753
2,291,844,631
325,881,244
978,224,317
840,320,705
2,193,423,560
518,768,296
27,470,751,802 24,589,810,592
23,033,340,533
19,775,552,465 18,408,161,859
3,503,349,070
3,046,390,500
5,269,474,690
5,269,474,690
1,689,636,958
1,689,636,958
294,950,950
294,950,950
1,349,578,805
1,406,527,880
7,667,220,373
6,701,180,881
1,341,619
-
17,128,128,177
2,517,678,100
5,269,474,690
1,689,636,958
294,950,950
1,466,602,600
5,889,784,879
-
3,312,618,059
1,151,400,702
610,628,150
1,550,589,207
3,116,703,964
1,469,621,611
499,622,784
1,147,459,569
3,257,050,368
1,890,074,651
403,598,795
963,376,922
4,382,581,278
2,776,266,125
754,903,558
383,170,553
141,582,304
3,064,944,769
1,526,449,918
664,712,728
470,097,685
128,598,961
2,648,161,988
1,642,216,008
363,744,181
523,798,136
101,559,917
973,367
325,685,371
1,020,948
274,064,529
1,361,452
15,482,294
27,470,751,802 24,589,810,592
23,033,340,533
2013
Amount in Taka
2012
2011
10,490,699,094
5,651,898,878
4,838,800,216
9,289,115,284
4,899,713,857
4,389,401,427
7,890,241,843
4,103,709,021
3,786,532,822
2,514,527,446
375,565,912
2,138,961,534
2,324,272,770
2,181,521,867
332,225,347
1,849,296,520
2,207,879,560
1,798,053,124
275,201,846
1,522,851,278
1,988,479,698
510,588,200
636,587,090
2,198,273,880
442,847,713
645,406,575
2,005,320,698
340,907,774
567,645,757
1,761,741,715
-104,679,709
-95,491,462
-83,892,463
2,093,594,171
-688,831,391
-324,415,546
-364,415,845
1,404,762,780
1,341,619
1,909,829,236
-590,439,908
-445,712,907
-144,727,001
1,319,389,328
-
1,677,849,252
-479,323,910
-207,549,905
-271,774,005
1,198,525,342
-
1,406,104,399
1,319,389,328
1,198,525,342
COMPANY X
Ratio
Current ratio
Acid test ratio
Average inventory turnover (days)
Return on assets
Gross profit margin
Net profit margin
Debt to Equity
EPS
PER
2011
2012
Company X Beximco Company X Beximco
4
2.70
4.1
2.67
3.1
1.83
3.3
1.88
34
203.85
36
181.32
32.20%
5.20%
33.00%
5.37%
81.20%
47.99%
83.30%
47.25%
25%
15%
29.50%
14.20%
90%
34%
95%
34%
2.5
4.76216
3.1
4.330992
20
19.65494
21
12.90697
2013
Company X Beximco
4.3
2.03
2.6
1.48
43
155.8
20.10%
0.05
78.10%
0.46
28.80%
0.13
89%
0.39
2.4
19
DESCRIPTION
ASSETS
Non-Current Assets
Intangible Assets
Current Assets
Inventories
Spares & Supplies
Accounts Receivable
TOTAL ASSETS
Shareholders Equity
Share Premium
Revaluation Surplus
Retained Earnings
Accrued Expenses
Dividend Payable
Income Tax Payable
2013
BDT
in %
18567329474
18364313070
198223509
4792895
8903422328
2411881986
433352407
1249434697
1186637111
3026383161
595732966
2012
2011
68 16392388639 66.663338368 15884877780 68.964715549

67 16201858216 65.888503514 15745492625 68.359570347
1
187079147 0.7607994633
135933879 0.5901613741
0
3451276 0.0140353907
3451276 0.0149838274
32
9
2
5
4
11
2
8197421953
2433987981
396175790
1162404807
965276373
2686598326
552978676
33.336661632
9.8983600215
1.6111380302
4.7271808079
3.9255136569
10.925656853
2.2488122628
7148462753
2291844631
325881244
978224317
840320705
2193423560
518768296
31.035284451
9.9501182979
1.4148240614
4.2469928129
3.6482797786
9.5228200046
2.2522494957
100 23033340533
100
27470751802
100 24589810592
19775552465
3503349070
5269474690
1689636958
294950950
1349578805
7667220373
1341619
72 18408161859
13 3046390500
19 5269474690
6 1689636958
1
294950950
5 1406527880
28 6701180881
0-
74.860933923 17128128177 74.362327742

12.388832718 2517678100 10.930581677
21.429504999 5269474690 22.877596424
6.8712890312 1689636958 7.3356140225
1.1994844324
294950950 1.2805391801
5.719962237 1466602600 6.3673030749
27.251860505 5889784879 25.570693363
-
3312618059
1151400702
610628150
1550589207
12
4
2
6
3116703964
1469621611
499622784
1147459569
12.674778247
5.9765470966
2.0318285175
4.6664026333
3257050368
1890074651
403598795
963376922
14.140590521
8.2058208113
1.7522373466
4.1825323627
4382581278
2776266125
754903558
383170553
141582304
973367
325685371
16
10
3
1
1
0
1
3064944769
1526449918
664712728
470097685
128598961
1020948
274064529
12.46428783
6.2076521992
2.7032039369
1.9117580562
0.4409256958
0.0059107883
0.0672168849
2648161988
1642216008
363744181
523798136
101559917
1361452
15482294
11.497081738
7.1297344198
1.5792072386
2.2740867103
0.4409256958
0.0059107883
0.0672168849
100 23033340533
100
27470751802
100 24589810592

Data Set

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Data Set

Uploaded by

Copyright:

Available Formats

DESCRIPTION

workings for common size Bank

Property, Plant and Equipment- Carrying

Spares & Supplies

Loans, Advances and Deposits

Short Term Investment

Cash and Cash Equivalents

EQUITY AND LIABILITIES

Issued Share Capital

Excess of Issue Price over Face Value of

Capital Reserve on Merger

Fair Value Gain on Investment

2013: 610628150*100/27470751802; 2012:

Deferred Tax Liability

Current Liabilities and Provisions

Short Term Borrowings

Long Term Borrowings-Current Maturity

2013: 754903558*100/27470751802; 2012:

Creditors and Other Payables

2013: 383170553*100/27470751802; 2012:

2013: 141582304*100/27470751802; 2012:

2013: 973367*100/27470751802; 2012:

Income Tax Payable

2013: 325685371*100/27470751802; 2012:

TOTAL EQUITY AND LIABILITIES

11,2012 & 2013

Beximco Pharmaceuticals Limited

Net Sales Revenue

Beximco Pharmaceuticals Limited

Net Sales Revenue

Cost of Goods Sold

Selling, Marketing and Distribution Expenses

Profit from Operations

Profit Before Contribution to WPPF

Profi t Before Tax

Income Tax Expenses

Deferred Tax Expense

Contribution to Workers Profi t

Profi t After Tax for the Year

Other Comprehensive Income

Total Comprehensive Income for the Year

Asset Turnover Ratio = Sales/ Average Total Assets

Number of Share outstanding

Price per share

Beximco Pharmaceuticals Limited

Net Sales Revenue

Turnover)- ( 365/Accounts Payable Turnover)

68 16392388639 66.663338368 15884877780 68.964715549

74.860933923 17128128177 74.362327742

You might also like